Neurology

Huntsville Memorial Hospital Reduces Patient Transfers and Enhances Local Care with Onsite EEG Program Powered by ZetoHuntsville Memorial Hospital Reduces Patient Transfers and Enhances Local Care with Onsite EEG Program Powered by Zeto

Huntsville Memorial Hospital Reduces Patient Transfers and Enhances Local Care with Onsite EEG Program Powered by Zeto

HUNTSVILLE, Texas, June 11, 2025 /PRNewswire/ -- Zeto, Inc. is proud to announce the success of a new onsite EEG…

13 hours ago
uniQure Announces Appointment of Kylie O’Keefe  as Chief Customer and Strategy OfficeruniQure Announces Appointment of Kylie O’Keefe  as Chief Customer and Strategy Officer

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE…

16 hours ago
Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.

Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.

Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral…

16 hours ago
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…

16 hours ago
Cabaletta Bio Announces Proposed Public Offering of SecuritiesCabaletta Bio Announces Proposed Public Offering of Securities

Cabaletta Bio Announces Proposed Public Offering of Securities

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company…

16 hours ago
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 CongressCabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively…

16 hours ago
Linical Celebrates 20 Years of Advancing Clinical Research and Patient WellbeingLinical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing

Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing

OSAKA, Japan, June 10, 2025 /PRNewswire/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th…

2 days ago
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumOragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for…

2 days ago
Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal DementiaPsilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia

Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia

Strategic agreement underscores Psilera's commitment to advancing PSIL-006 with precision neurology approach Results are expected in Q3 2025 ORLANDO, Fla.…

3 days ago
Rose Hill Life Sciences Executes Exclusive License Agreement with Johns Hopkins University for Restoration of Motor Function Post-Neurological Injury Using PsychedelicsRose Hill Life Sciences Executes Exclusive License Agreement with Johns Hopkins University for Restoration of Motor Function Post-Neurological Injury Using Psychedelics

Rose Hill Life Sciences Executes Exclusive License Agreement with Johns Hopkins University for Restoration of Motor Function Post-Neurological Injury Using Psychedelics

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Rose Hill Life Sciences, a global leader in the research and intellectual property…

1 week ago